[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-cancer-stage-ii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-cancer-stage-ii":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100453048","profiling-based-endometrial-cancer-adjuvant-therapy-100453048",false,"NCT05179447","PROfiling Based Endometrial Cancer Adjuvant Therapy","Randomized Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Therapy for Women With Early Stage Endometrioid Adenocarcinoma","PROBEAT","Inclusion Criteria:\n\n1. Surgery consisting of a total abdominal or laparoscopic hysterectomy, bilateral salpingectomy, pelvic lymphadenectomy or sentinel lymph node mapping and dissection, with or without para-aortic lymphadenectomy, oophorectomy\n2. Histologically confirmed endometrioid type endometrial carcinoma, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage I, with one of the following combinations of stage and grade:\n\n   Stage I A, grade 3 Stage I B, grade 1 or 2 Stage I B, grade 3 Stage II\n3. World Health Organization (WHO)-performance status 0-2\n4. Written informed consent\n\nExclusion Criteria:\n\n1. With residual disease\n2. Any other stage and type of endometrial carcinoma\n3. Histological types serous carcinoma or clear cell carcinoma (at least 10% if mixed type), or undifferentiated or neuroendocrine carcinoma\n4. Uterine sarcoma (including carcinosarcoma)\n5. Previous malignancy (except for non-melanomatous skin cancer)\n6. Previous pelvic radiotherapy\n7. Expected interval between the operation and start of radiotherapy exceeding 8 weeks","FEMALE","18 Years","75 Years",{"count":21,"type":22},590,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.",[28,29],"Endometrial Cancer Stage I","Endometrial Cancer Stage II","RECRUITING","2025-03-26",{"date":33,"type":34},"2025-04-01","ACTUAL",{"date":36,"type":34},"2022-01-24",{"date":38,"type":22},"2027-01-01",{"name":40,"class":41},"Women's Hospital School Of Medicine Zhejiang University","OTHER",10]